MoveSurge

Sellas Life Sciences says galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint, reducing death risk by 41% in AML patients in second remission

Observed price moves

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.

Share